← Back to Search

Brachytherapy

HDR vs. LDR Brachytherapy for Prostate Cancer

Phase 3
Waitlist Available
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG 0-1
Clinical stage T1c-T2b, PSA < 20, Gleason < 8
Must not have
Prior pelvic radiation
Prior radical surgery for carcinoma of the prostate,
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-10 years
Awards & highlights

Summary

This trial will offer men with intermediate risk prostate cancer the opportunity to be randomized between low dose rate brachytherapy and high dose rate brachytherapy. Men will also be offered the opportunity to test the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.

Who is the study for?
Men with intermediate risk prostate cancer who haven't had pelvic radiation, prostate surgery, chemotherapy for prostate cancer, or certain other prostate treatments. They should have a clinical stage T1c-T2b, PSA < 20 ng/ml, Gleason score < 8, and be in good physical condition (ECOG 0-1). Their tumor characteristics must meet specific criteria and they can't be eligible for just monitoring the cancer without treatment.Check my eligibility
What is being tested?
The trial is comparing two types of internal radiation therapy: Low Dose Rate (LDR) brachytherapy involving permanent radioactive seeds and High Dose Rate (HDR) temporary brachytherapy. Participants will be randomly assigned to one of these treatments to see which is more effective at treating intermediate risk prostate cancer.See study design
What are the potential side effects?
Possible side effects from both LDR and HDR brachytherapy may include discomfort or pain during the procedure, urinary issues like frequency or urgency, bowel changes such as diarrhea or rectal bleeding, erectile dysfunction, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My prostate cancer is in an early stage, with low PSA and Gleason scores.
Select...
My prostate cancer is early stage, with specific PSA and Gleason scores.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had radiation therapy to my pelvic area before.
Select...
I have had major surgery for prostate cancer.
Select...
I have had surgery or cryotherapy for prostate issues.
Select...
I have had chemotherapy for prostate cancer before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The difference in Quality of Life in the urinary domain between LDR and HDR brachytherapy.
Secondary outcome measures
Acute and long term toxicity
Biochemical Outcome
Cell cycle progression score
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: High dose rate brachytherapyExperimental Treatment1 Intervention
Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required. HDR brachytherapy is also accomplished as an out-patient.
Group II: Low dose rate brachytherapyActive Control1 Intervention
Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
LDR brachytherapy involves permanently implanting radioactive seeds in the prostate, which emit radiation over time to kill cancer cells. HDR brachytherapy uses a temporary radioactive source inserted through catheters, delivering a high dose of radiation in a short period before removal. Both treatments aim to maximize radiation to the tumor while minimizing damage to surrounding tissues. Understanding these mechanisms helps patients make informed decisions about their treatment options and potential side effects.

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,427 Total Patients Enrolled
23 Trials studying Prostate Cancer
5,752 Patients Enrolled for Prostate Cancer
Ross Halperin, MDStudy DirectorBritish Columbia Cancer Agency Program Director
1 Previous Clinical Trials
140 Total Patients Enrolled
1 Trials studying Prostate Cancer
140 Patients Enrolled for Prostate Cancer

Media Library

High Dose Rate Prostate Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02692105 — Phase 3
Prostate Cancer Research Study Groups: Low dose rate brachytherapy, High dose rate brachytherapy
Prostate Cancer Clinical Trial 2023: High Dose Rate Prostate Brachytherapy Highlights & Side Effects. Trial Name: NCT02692105 — Phase 3
High Dose Rate Prostate Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02692105 — Phase 3
~7 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top